BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, December 5, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Nabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infections
To read the full story,
subscribe
or
sign in
.
Infection
Nabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infections
Nov. 9, 2022
Nabriva Therapeutics AG has identified 12-epi-mutilin derivatives reported to be useful for the treatment of bacterial infection.
BioWorld Science
Infection
Patents